Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice short! You’re obviously very proud! Wall Street is next for you.
This thing will run with so little buying. Unreal. $mslp
Any idea on timeline? Is that a 30 day process? 10 day? I like the idea of trading in a better regulated market. I’m sure other investors will too.
Any idea when this thing hits the OTC again? It’ll be nice getting this off the pinks again. I anticipate increased volume from that move. I’m liking what I’m seeing so far with the recent moves. Anything over $2.00 to $3.00 and I think I’m satisfied for the short term. Buyout price over that would be great. With a company thats set up to start making money, 1.0 - 1.5 x sales certainly isn’t out of the question and would take us to about double the pps now. Profitable company in this space, showing healthy revenue growth, should command a market valuation of no less than 2.0 - 4.0x sales. $MSLP
Until they’re bought out, yes. I’ll be here.
Big investors are cashing out? 500k shares have exchanged hands today. Show the proof. I haven’t seen a Schedule 13D or 13G. Please post it if you have.
Lol I like your logic. Yes, keep it up...all the way to $10.
Incremental moves to $10. Waiting patiently until fourth quarter sales come in! With the recent drastic move over $5 and touching $6 briefly over the last few days I feel something big is coming!
“The recent FDA approval of Gimoti, the first and only outpatient treatment option that bypasses the stomach to relieve symptoms in adults with acute and recurrent diabetic gastroparesis, marked the most significant milestone in our history,” said David A. Gonyer, R.Ph., President and CEO of Evoke Pharma. “We are currently focused on the commercial launch of Gimoti during the fourth quarter of 2020 with EVERSANA, our commercial partner. EVERSANA is working with us to fully implement our strategy, while leveraging their integrated suite of commercialization capabilities. Simultaneously, we have manufactured the first commercial batch of Gimoti with our contract manufacturing partner, Patheon. We believe that we will be well prepared to launch Gimoti and look forward to providing patients with diabetic gastroparesis the only outpatient non-oral treatment option to help improve gastroparesis patients’ quality of life.”
$EVOK
Over $2 per share increase in last 30 days. People are accumulating.
Cheers!
Proof? Where is the pump? Haven’t seen news since earnings. Without evidence of your claims, there are worthless. It touched $6 today. Only going up to $10. Watch for buyout over $10 within 6 months to 1 year mark.
Incremental moves to $10. Waiting patiently until fourth quarter sales come in! Over a million shares traded in premarket. Something big coming!
“The recent FDA approval of Gimoti, the first and only outpatient treatment option that bypasses the stomach to relieve symptoms in adults with acute and recurrent diabetic gastroparesis, marked the most significant milestone in our history,” said David A. Gonyer, R.Ph., President and CEO of Evoke Pharma. “We are currently focused on the commercial launch of Gimoti during the fourth quarter of 2020 with EVERSANA, our commercial partner. EVERSANA is working with us to fully implement our strategy, while leveraging their integrated suite of commercialization capabilities. Simultaneously, we have manufactured the first commercial batch of Gimoti with our contract manufacturing partner, Patheon. We believe that we will be well prepared to launch Gimoti and look forward to providing patients with diabetic gastroparesis the only outpatient non-oral treatment option to help improve gastroparesis patients’ quality of life.”
$EVOK
Next stop $5.00. Then $10 here we come. Let’s freaking go!!! $EVOK
Also in filing....enough cash to survive through end of year without revenue from Gimoti. See you at $10
Panic is setting in. You can always tell by the frequency of postings. Lol see ya at $10. This doesn’t look like to right stock to short at this point.
Incremental moves to $10. Waiting patiently until fourth quarter sales come in!
“The recent FDA approval of Gimoti, the first and only outpatient treatment option that bypasses the stomach to relieve symptoms in adults with acute and recurrent diabetic gastroparesis, marked the most significant milestone in our history,” said David A. Gonyer, R.Ph., President and CEO of Evoke Pharma. “We are currently focused on the commercial launch of Gimoti during the fourth quarter of 2020 with EVERSANA, our commercial partner. EVERSANA is working with us to fully implement our strategy, while leveraging their integrated suite of commercialization capabilities. Simultaneously, we have manufactured the first commercial batch of Gimoti with our contract manufacturing partner, Patheon. We believe that we will be well prepared to launch Gimoti and look forward to providing patients with diabetic gastroparesis the only outpatient non-oral treatment option to help improve gastroparesis patients’ quality of life.”
$EVOK
It’s going to $10 whether you like it or not but for my sake, I’m seriously hoping it drops to $2 again so I can load up.
He’s back! Over a month of posting the same message? This stock is still way undervalued. $10 short term target!
$8-$10 per share gives this a market cap around $300 million. Totally realistic with the new FDA approval and future fall sales of Gimoti. $EVOK
Agree. Production and Distribution all day long. $EVOK is going to the big leagues with their innovative new product Gimoti. Can’t wait to see what the potential is for this company when doctors are prescribing the drug and sales figures start rolling in. $8 to $10 easy from these levels in my opinion. $10 is also the average price target from the analysts covering Evoke. $10 pps gives this a $280 million dollar market cap. Realistic for a first if it’s kind delivery system for metoclopramide.
Or you could listen to someone scream the stocks going to $2 10 times a day for 6 weeks. Sounds legit.
I do have a question...you say “mark your words” however you have stated this very thing (falling to $2.00) for the last 6 weeks or so. If the price doesn’t drop to $2.00, which is not likely, does that mean you are/were clearly wrong and essentially lying to board members? Sincerely curious. $EVOK
Average volume 648k shares traded. Volume today 272k. One would gather from the volume that no one is existing here at a rapid rate. My assumption is that there are still many people slowly accumulating leading up to news regarding first sales figures. I expect a ride up to $10 per share. $EVOK
Clearly you’re in the wrong message board. I suggest researching a few penny stocks on the pinks. See you at $10 $EVOK
Looks like you’re wrong again. It’s going the wrong a way. $10 here we come. $EVOK
$10 baby $10! Mark my words. $EVOK
You do realize you have been posting the same message since June 21, right? Bell345? $EVOK
Looks like things are continuing to progress in the manufacturing front. Can’t wait to see where $EVOK is come October / November. Certainly not $2.00 Hahahaha
Still going with the $2.00 thing huh? I’ll see your $2.00 and raise you to $10 plus in coming months. You do realize that they have a recently approved FDA drug correct? $EVOK
We can only hope that this falls below $2 again. Not likely. This will be $10 soon enough. Good luck $EVOK longs.
I think we’re going to hover around here for a bit until we get another update. I truly feel $8 to $10 is on the table.
Side note....Can you imagine a life so pathetic that you choose to post the same message over and over on a stock board? On top of that, a message that is completely false. Lol
$EVOK
Evoke $10 per share puts this around a $250 million valuation. Completely feasible with their Gimoti product, first of its kind nasal spray for gastroperesis. I can see this hovering around the $3.50 levels until more news comes out or buyout is announced. $EVOK
Here you go! Looks legit to me! See you at $10.
[url][/url][tag] https://www.gimotirx.com/[/tag]
$EVOK
Told us what? You said $2.00. I haven’t seen $2 or even close. I have however seen where the FDA has posted the Gimoti approval on their official website. I have also seen where the share price has maintained aprox 30% of its gain following the approval. $EVOK
It’s official... we’re on the FDA’s website.
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/209388Orig1s000ltr.pdf
Found this posted on another board and also in an article online. Link below. Website requires you to sign up to access article.
https://www.empr.com/home/news/gimoti-metoclopramid-evoke-nasal-spray-acute-recurrent-diabetic-gastroparesis/
H.C. Wainwright Upgraded Evoke Pharma (EVOK) this morning to Buy. New Target price of $10 per share.
It’s going to be a great day all! FDA approval in hand. Let’s go! Lots of pre market action! $EVOK
$10 = aprox $240 million dollar market cap.
$15 = $370 million dollar
I think either are realistic. Gastroparesis drug market between $4 and $6 billion.
Aprox. Cost of monthly metoclopramide pill form per prescription cost $25. Gimoti most likely will be at least $25 if not higher.
2017 metoclopramide was 253rd most prescribed drug in US with more than 1 million prescriptions in our country alone.
Studies have shown that up to 4% of population could experience gastroparesis. Good luck all! Feeling good about the future! $EVOK long
Example for everyone.... you’ve posted here twice since Friday. Not following Evoke but yet you’re an expert on the subject matter and trying to save investors from losses. Sounds a bit sketch to me but again, only my opinion. How’s the saying go....if it smells like...